首页膀胱肿瘤诊断证据详情

Evaluating patient-reported outcome measures (PROMs) for bladder cancer: a systematic review using the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) checklist

原文: 2018 年 发布于 International Journal of Environmental Research and Public Health 6 卷 第 4 期 3246-3258 浏览量:164次

作者: Mason S. J. Catto J. W. F. Downing A. Bottomley S. E. Glaser A. W. Wright P.

作者单位: Department of Urology, Houston Methodist Hospital, Houston, TX, United States. Department of Urology, University of Texas Health, San Antonio, TX, United States. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, NY, United States. USC Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States. Division of Urology, Medical College of Georgia, Augusta University, Augusta, GA, United States. Division of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. Division of Urology, University of Toronto, Toronto, ON, Canada. Division of Urology, Mount Sinai Hospital, Toronto, ON, Canada.

归属分类: 膀胱肿瘤诊断证据

DOI: 10.5173/ceju.2023.252

关键词: Carcinogenesis Carcinoma Renal Cell/*epidemiology/mortality Humans Kidney Neoplasms/*epidemiology/mortality Tobacco Smoking/*adverse effects Urinary Bladder Neoplasms/*epidemiology/mortality Bladder cancer Kidney cancer Tobacco smoking

文献简介

Background: Emerging evidence suggested that statins might decrease the risk of cancer. This study examined the associations of statin use with the risk of main urologic cancer, and a sex-specific relationship between statin use and the risk of cancer was also evaluated. Methods: A literature search in PubMed, MEDLINE, and Web of Science databases was undertaken through February 2017 evaluating the association between statin use and risk of main urologic cancer. Pooled relative risk (RR) estimates and 95% confidence intervals (CIs) were calculated using random-effects model. In addition, we also estimated RR ratios (RRRs) between men and women. Results: A total of 30 cohort studies contributed to the analysis. The results of the meta-analysis showed that statin users did not experience a significantly decreased risk for developing kidney cancer in both women and men (RR = 1.01, 95% CI = 0.91-1.11). Statin use in women had the reduced tendency for the risk of kidney cancer, but statin use in men had an adverse tendency for the risk of this disease (Women: RR = 0.98, 95% CI = 0.85-1.12; Men: RR = 1.09, 95% CI = 0.99-1.19). The pooled multiple-adjusted women-to-men RRR for incident kidney cancer was 0.90 (95% CI = 0.75-1.05). Compared to non-users, statin users yielded the reduced risk of total, advanced, high-grade, and low-grade prostate cancer by approximately 12%, 18%, 14% and 7% (Total: RR = 0.88, 95% CI = 0.84-0.93; Advanced: RR = 0.82, 95% CI = 0.70-0.95; High-grade: RR = 0.86, 95% CI = 0.68-0.99; Low-grade: RR = 0.93, 95% CI = 0.86-0.99), whereas the significant effects were not observed for bladder cancer (RR = 1.03, 95% CI = 0.88-1.17). Conclusions: The results found that sex difference could affect the association of statin use with the risk of kidney cancer. The statin use could reduce the risk of prostate cancer but no associations were found between statin use and bladder cancer.

热门文献